302 related articles for article (PubMed ID: 24685447)
1. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
[TBL] [Abstract][Full Text] [Related]
2. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
Wang T; Zhou J; Tian S; Wang Y; Patel P; Jani AB; Langen KM; Curran WJ; Liu T; Yang X
Br J Radiol; 2020 Mar; 93(1107):20190845. PubMed ID: 31904261
[TBL] [Abstract][Full Text] [Related]
3. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
[TBL] [Abstract][Full Text] [Related]
4. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
[TBL] [Abstract][Full Text] [Related]
6. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
[TBL] [Abstract][Full Text] [Related]
7. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
[TBL] [Abstract][Full Text] [Related]
9. Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study.
Ong ALK; Knight K; Panettieri V; Dimmock M; Tuan JKL; Tan HQ; Wright C
Front Oncol; 2023; 13():1241711. PubMed ID: 38023170
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers.
Osman SOS; Fairmichael C; Whitten G; Lundy GS; Wesselman R; Wilson ML; Hounsell AR; Prise KM; Irvine D; McGarry CK; Jain S
Radiat Oncol; 2022 Feb; 17(1):38. PubMed ID: 35193630
[TBL] [Abstract][Full Text] [Related]
12. Ultra hypofractionated extended nodal irradiation using volumetric modulated arc therapy for oligorecurrent pelvic nodal prostate cancer.
Slevin F; Thompson CM; Speight R; Murray LJ; Lilley J; Henry AM
Med Dosim; 2021 Winter; 46(4):411-418. PubMed ID: 34148727
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
Yoo S; Wu QJ; Lee WR; Yin FF
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):935-42. PubMed ID: 20044214
[TBL] [Abstract][Full Text] [Related]
14. Conformal irradiation of concave-shaped PTVs in the treatment of prostate cancer by simple 1D intensity-modulated beams.
Fiorino C; Broggi S; Corletto D; Cattaneo GM; Calandrino R
Radiother Oncol; 2000 Apr; 55(1):49-58. PubMed ID: 10788688
[TBL] [Abstract][Full Text] [Related]
15. Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer.
Corletto D; Iori M; Paiusco M; Brait L; Broggi S; Ceresoli G; Iotti C; Calandrino R; Fiorino C
Radiother Oncol; 2003 Feb; 66(2):185-95. PubMed ID: 12648791
[TBL] [Abstract][Full Text] [Related]
16. Megavoltage cone beam computed tomography dose and the necessity of reoptimization for imaging dose-integrated intensity-modulated radiotherapy for prostate cancer.
Akino Y; Koizumi M; Sumida I; Takahashi Y; Ogata T; Ota S; Isohashi F; Konishi K; Yoshioka Y
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1715-22. PubMed ID: 21620584
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.
Devlin L; Dodds D; Sadozye A; McLoone P; MacLeod N; Lamb C; Currie S; Thomson S; Duffton A
Br J Radiol; 2020 Apr; 93(1108):20190789. PubMed ID: 31971829
[TBL] [Abstract][Full Text] [Related]
18. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treament planning comparison.
Fellin F; Azzeroni R; Maggio A; Lorentini S; Cozzarini C; Di Muzio N; Fiorino C; Calandrino R; Schwarz M
Radiother Oncol; 2013 May; 107(2):207-12. PubMed ID: 23541644
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study.
Kim YJ; Yoon KJ; Kim YS
Sci Rep; 2020 Sep; 10(1):14713. PubMed ID: 32895442
[TBL] [Abstract][Full Text] [Related]
20. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
[No Abstract] [Full Text] [Related]
[Next] [New Search]
